Walgreen Boots Alliance

WBA-Q

NASDAQ:WBA

42.96
1.13 (2.69%)
Walgreens Boots Alliance, Inc. is an American holding company headquartered in Deerfield, Illinois that owns Walgreens, Boots, and a number of pharmaceutical manufacturing, wholesale and distribution companies.
More at Wikipedia

Analysis and Opinions about WBA-Q

Signal
Opinion
Expert
BUY
BUY
June 14, 2019

$79.57 is his model price, 50% higher than the current price. Dirt cheap now. He has recommended this in the past. The Amazon fear is overdone. Be patient with this value name.

Show full opinionHide full opinion

$79.57 is his model price, 50% higher than the current price. Dirt cheap now. He has recommended this in the past. The Amazon fear is overdone. Be patient with this value name.

N/A
N/A
May 30, 2019
He was not happy with their last earnings report. There was a weakening on margins on their generic drug business and they are being affected with BREXIT because of their affiliation with Boots. He owns CVS-N who have a more vibrant long term plan. WBA-Q does not have a catalyst.
Show full opinionHide full opinion
He was not happy with their last earnings report. There was a weakening on margins on their generic drug business and they are being affected with BREXIT because of their affiliation with Boots. He owns CVS-N who have a more vibrant long term plan. WBA-Q does not have a catalyst.
HOLD
HOLD
May 29, 2019
He sill owns WBA-Q. Both have been under tremendous pressure. He feels the entry of Amazon in to mail order prescriptions has hurt along with a move towards generic pricing on drugs. He feels it is way over done. These companies are foundations within the US. At some point they will bottom out, but he is not ready to add to his holdings at this point.
Show full opinionHide full opinion
He sill owns WBA-Q. Both have been under tremendous pressure. He feels the entry of Amazon in to mail order prescriptions has hurt along with a move towards generic pricing on drugs. He feels it is way over done. These companies are foundations within the US. At some point they will bottom out, but he is not ready to add to his holdings at this point.
BUY
BUY
May 23, 2019
It is global. It will have headline noise because of the election. It could bounce back but is under pressure from dispensing fees. There are other ways to get dividend growth. 75% of their business is retail.
Show full opinionHide full opinion
It is global. It will have headline noise because of the election. It could bounce back but is under pressure from dispensing fees. There are other ways to get dividend growth. 75% of their business is retail.
BUY
BUY
April 22, 2019
vs. Walgreen Still cheap. $82.60 is his target price. Some stocks you go to war with when the market or sector is negative, when investors beat up a stock. You can be contrarian and do very well with this.
Show full opinionHide full opinion
vs. Walgreen Still cheap. $82.60 is his target price. Some stocks you go to war with when the market or sector is negative, when investors beat up a stock. You can be contrarian and do very well with this.
PAST TOP PICK
PAST TOP PICK
April 22, 2019
(A Top Pick Apr 25/18, Down 16%) He sold upon news that its generic drug margins were deteriorating. You must look at your stocks with fresh eyes when news arises. Have an unemotional sell discipline.
Show full opinionHide full opinion
(A Top Pick Apr 25/18, Down 16%) He sold upon news that its generic drug margins were deteriorating. You must look at your stocks with fresh eyes when news arises. Have an unemotional sell discipline.
PARTIAL BUY
PARTIAL BUY
April 11, 2019
The PE is lower than historically. He historically owned CVS-N. The problem with WBA-N is the political noise around drug pricing and these companies are just middlemen. He sold CVS-N a while ago. There is a lot of risk in the names for the next 5 years. Buy a half position in the name and buy the rest on later on weakness.
Show full opinionHide full opinion
The PE is lower than historically. He historically owned CVS-N. The problem with WBA-N is the political noise around drug pricing and these companies are just middlemen. He sold CVS-N a while ago. There is a lot of risk in the names for the next 5 years. Buy a half position in the name and buy the rest on later on weakness.
TOP PICK
TOP PICK
March 13, 2019
It's suffered the double-whammy of eliminating drug pricing talk by politicians in the U.S. and fears of Amazon getting into the pharma space. WBA has increased its dividend 43 years in a row and expect one in June. Trades at lower than 10x earnings. He thinks pricing fears are overblown. Targets this in the mid-$70s within 12 months. (Analysts’ price target is $74.35)
Show full opinionHide full opinion
It's suffered the double-whammy of eliminating drug pricing talk by politicians in the U.S. and fears of Amazon getting into the pharma space. WBA has increased its dividend 43 years in a row and expect one in June. Trades at lower than 10x earnings. He thinks pricing fears are overblown. Targets this in the mid-$70s within 12 months. (Analysts’ price target is $74.35)
BUY
BUY
March 11, 2019
He decided to get out of CVS-T because they were on the defensive too much. In the US a lot of funding for drugs comes from the government. They are always looking for ways to bring down healthcare costs in the US. CVS-T keep making acquisitions to make the company make sense. He would probably prefer WBA-Q.
Show full opinionHide full opinion
He decided to get out of CVS-T because they were on the defensive too much. In the US a lot of funding for drugs comes from the government. They are always looking for ways to bring down healthcare costs in the US. CVS-T keep making acquisitions to make the company make sense. He would probably prefer WBA-Q.
DON'T BUY
DON'T BUY
March 11, 2019
It looks shaky now. Hopefeully it stays in the $60-80 range. If it breaks below $60, you're in trouble. Have a short leash on this.
Show full opinionHide full opinion
It looks shaky now. Hopefeully it stays in the $60-80 range. If it breaks below $60, you're in trouble. Have a short leash on this.
PAST TOP PICK
PAST TOP PICK
December 21, 2018
(A Top Pick Nov 30/17, Down 3%) Holding its own given the recent drop in markets in general. Just in the last week it has weaken based on a weak report from GoldmanSachs. They have recently guided earnings in line with market expectations. The European market slowdown is creating headwinds. It trades at less than 10 times earnings and over 2% yield with rising dividends expected next year.
Show full opinionHide full opinion
(A Top Pick Nov 30/17, Down 3%) Holding its own given the recent drop in markets in general. Just in the last week it has weaken based on a weak report from GoldmanSachs. They have recently guided earnings in line with market expectations. The European market slowdown is creating headwinds. It trades at less than 10 times earnings and over 2% yield with rising dividends expected next year.
BUY
BUY
December 19, 2018
They have 13,000 stores in the US and just bought many more stores recently. They struggled to bring those into the structure, but feels they are going to do well. Trading at 12.5 times earnings (about 30% discount to normal). It is a Dow component. He thinks there are good things to come.
Show full opinionHide full opinion
They have 13,000 stores in the US and just bought many more stores recently. They struggled to bring those into the structure, but feels they are going to do well. Trading at 12.5 times earnings (about 30% discount to normal). It is a Dow component. He thinks there are good things to come.
WAIT
WAIT
December 3, 2018
Maybe the CVS acqusition of Aetna is synergistic by putting Aetna facilities besides CVS locations, but will this drive volume within the pharamcy? He's not sure. Trades at 10x earnings. With this purchase, their debt is higher. Wait a couple of quarters to see if the acqusition pans out.
Show full opinionHide full opinion
Maybe the CVS acqusition of Aetna is synergistic by putting Aetna facilities besides CVS locations, but will this drive volume within the pharamcy? He's not sure. Trades at 10x earnings. With this purchase, their debt is higher. Wait a couple of quarters to see if the acqusition pans out.
BUY
BUY
November 26, 2018
He likes this company. It has been trading quite well. It looks undervalued and a nice little dividend which is sustainable. A good opportunity here.
Show full opinionHide full opinion
He likes this company. It has been trading quite well. It looks undervalued and a nice little dividend which is sustainable. A good opportunity here.
TOP PICK
TOP PICK
November 2, 2018
This sector was hit when Amazon was thought to be invading the space. His model has just given a positive buy signal. His model price is $100. Yield 2.2%. (Analysts’ price target is $76.14)
Show full opinionHide full opinion
This sector was hit when Amazon was thought to be invading the space. His model has just given a positive buy signal. His model price is $100. Yield 2.2%. (Analysts’ price target is $76.14)
Showing 16 to 30 of 211 entries